<SEC-DOCUMENT>0001144204-14-004825.txt : 20140130
<SEC-HEADER>0001144204-14-004825.hdr.sgml : 20140130
<ACCEPTANCE-DATETIME>20140130091514
ACCESSION NUMBER:		0001144204-14-004825
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140130
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140130
DATE AS OF CHANGE:		20140130

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1228

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		14559050

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v366700_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section&nbsp;13 or 15(d) of
the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of Earliest Event Reported):
January 30, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 18pt"><U>STAAR Surgical
Company</U></FONT><BR>
<FONT STYLE="font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 33%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Delaware</U><br>
(State or other jurisdiction&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)</P></td>
    <TD STYLE="width: 34%; padding-right: 0; padding-left: 0; text-align: center; font-size: 10pt; padding-bottom: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>0-11634</u></font><br>
<font style="font: 10pt Times New Roman, Times, Serif">&nbsp;(Commission File Number)</font></td>
    <TD STYLE="width: 33%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>95-3797439</U><br>
(I.R.S. Employer&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; font-size: 10pt; padding-bottom: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; font-size: 10pt; padding-bottom: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">1911 Walker Ave, Monrovia, California (Address of principal executive offices)</font></td>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; font-size: 10pt; padding-bottom: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; font-size: 10pt; padding-bottom: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>91016</u></font><br>
<font style="font: 10pt Times New Roman, Times, Serif">(Zip Code)</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not
Applicable&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Former name or former address, if changed since last report</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
                            5.02</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 30, 2014, the Board of Directors
of STAAR Surgical Company elected Kathryn Tunstall, 63, to serve in a newly created seat pursuant to an increase in size of the
Board from six to seven members. Ms. Tunstall will not serve as a member of any Company committees at this time. The Board approved
providing Ms. Tunstall with the standard director compensation for a director, pro-rated for the remaining portion of the 2013-2014
term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From 2000 to 2013, Ms. Tunstall served as
Chairman of Conceptus, Inc., a developer, maker, and marketer of medical devices for women. Ms. Tunstall served as Conceptus&rsquo;
first President and Chief Executive Officer from 1993-2000. In 2013 Conceptus was acquired by Bayer AG for $1.1 billion. Prior
to joining Conceptus in 2000, Ms. Tunstall served for seven years in executive leadership roles with Baxter International, most
recently as President of the Company&rsquo;s Edwards Less Invasive Surgery Division. She also spent more than 12 years in various
marketing, finance and operational roles with divisions of American Hospital Supply, including McGaw Laboratories, a division that
manufactured and sold medical equipment and disposable supplies. She received her B.A. in Economics from the University of California-
Santa Barbara.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The appointment of Ms. Tunstall to the Board
was not the result of any arrangement or understanding between her and any other person or entity. There are no transactions between
Ms. Tunstall nor any member of her immediate family and the Company or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
                            7.01</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Regulation
FD Disclosure</B>.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 30, 2014, the Company published
a press release regarding the election of Ms. Tunstall to the Board, and an increase in the size of the Board from six to seven
members. The Company also announced the election of Mr. Mark Logan to assume the role of Chairman of the Board in a planned transition.
A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information furnished herewith pursuant
to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be &ldquo;filed&rdquo; for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities
of that section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any filing under
the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless
of any general incorporation language in the filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 8.01</B></TD><TD STYLE="text-align: justify"><B>Other Events</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 30, 2014, the Board of Directors
of STAAR Surgical Company elected Mr. Mark Logan to assume the role of Chairman of the Board. Mr. Logan, who joined the Board in
2010, currently serves as Chairman of the Compensation Committee and as a member of the Nominating and Governance Committee. Mr.
Logan will succeed Mr. Don Bailey, who will remain a member of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
                            9.01</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Financial
Statements and Exhibits</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 10%"><font style="font: 10pt Times New Roman, Times, Serif"><u>Exhibit No.</u></font></td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 85%"><font style="font: 10pt Times New Roman, Times, Serif"><u>Description</u></font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD><font style="font: 10pt Times New Roman, Times, Serif">99.1</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">Press release of the Company dated January 30, 2014.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">January 30, 2014</font></td>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">By:&nbsp;<u>/s/ Barry G. Caldwell&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Barry G. Caldwell</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;President and Chief Executive Officer</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v366700_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; color: Red"><B><IMG SRC="image_002.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="color: #BF0000; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">KATHRYN
TUNSTALL APPOINTED TO STAAR SURGICAL<BR>
BOARD OF DIRECTORS</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Appointment Expands Board to Seven Members</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal; font-style: normal">MONROVIA,
CA, January 30, 2014 -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses
for the eye, today announced the appointment of Kathryn Tunstall to its Board of Directors. Ms. Tunstall brings nearly 40 years
of leadership experience in the pharmaceutical and medical device industry, most recently serving for the past 13 years as Chairman
of Conceptus, Inc., a developer, maker, and marketer of medical devices for women. In 2013 Conceptus was acquired by Bayer AG for
$1.1 billion. Her appointment expands the number of directors to seven. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Kathryn is an accomplished, well-respected, thought leader
in the health care industry with a proven track record of building shareholder value. Her complementary background and passion
for innovative medical technology makes her an excellent addition to our board. Kathryn&rsquo;s own personal experience led to
her understanding of the value the Internet can bring to medical devices and we look forward to adding this knowledge to our board,&quot;
said Randy Meier, Chairman of STAAR&rsquo;s Nominating Committee.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal; font-style: normal">In
addition to her position as Chairman of Conceptus, Ms. Tunstall served as the company&rsquo;s first President and Chief Executive
Officer from 1993-2000. During her tenure with Conceptus, the company achieved a number of major milestones, including an expedited
FDA approval of the first non-surgical female permanent contraceptive device and twice being recognized as one of Silicon Valley&rsquo;s
fastest growing companies. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;I&rsquo;m very impressed with STAAR&rsquo;s competitive
positioning, innovation, and management&rsquo;s drive to successfully bring superior refractive technologies to the worldwide market.
In recent years the Company has made exceptional progress and is on the verge of a very positive transformation. The increased
strength of the balance sheet and current operating leverage, as well as the strong pipeline of new products, presents an exciting
opportunity for the Company to increase shareholder value,&rdquo; said Ms. Tunstall.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal; font-style: normal">Prior
to joining Conceptus in 2000, Ms. Tunstall served for seven years in executive leadership roles with Baxter International, most
recently as President of the Company&rsquo;s Edwards Less Invasive Surgery Division. She also spent more than 12 years in various
marketing, finance and operational roles with divisions of American Hospital Supply, including McGaw Laboratories, a division that
manufactured and sold medical equipment and disposable supplies. She received her B.A. in Economics from the University of California-
Santa Barbara.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ms. Tunstall&rsquo;s prior corporate governance experience includes
both private and public boards. She currently serves on the board of Auxogyn, Inc., a venture-backed medical technology company
focused on women&rsquo;s reproductive health. Ms. Tunstall previously served as chairman of two private development-stage companies
she co-founded; Fair Advantage Inc., a development-stage educational company and HopeLink Corporation, an information solutions
company for improving new product development efforts in the bio-pharmaceutical industry by locating and enrolling patients in
treatment trials. Ms. Tunstall also served as a director, chair of the compensation committee and the audit committee for Caliper
Life Sciences, a publicly-traded provider of leading-edge technologies enabling researchers to create medicines and diagnostic
tests more quickly and efficiently. Caliper was acquired by PerkinElmer in 2011 for $600 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STAAR also announced today that Don M. Bailey, the Company&rsquo;s
Chairman of the Board since 2005, is turning over the chairman&rsquo;s role to Mark Logan in a planned transition. &ldquo;During
the past few years, the management team at STAAR has well executed on its plan to generate value for the Company&rsquo;s shareholders.
I'm very proud to have been a part of this progress, which now presents an opportune time for me to transition from the Chair position
while still remaining a director,&quot; said Mr. Bailey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. <FONT STYLE="font-family: Times New Roman, Times, Serif">Logan
was appointed to the STAAR board in 2010 and serves as the Chair of the Compensation Committee. He has 35 years of executive level
experience in the health care products industry and is currently co-founder and President and CEO of TearSolutions, L.L.C. Mr.
Logan also serves as a non-executive Director at VIVUS, Inc., as a member of the board at the University of Virginia Heart &amp;
Vascular Center, as a director of Public Policy Virginia, Inc. and as a trustee of the Southern Environmental Law Center. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Mr.
Logan served as Chairman and Chief Executive Officer of VISX, Inc. from 1994 to 2001. VISX was acquired by Advanced Medical Optics,
and subsequently by Abbott Laboratories in 2009. Prior to joining VISX, he was Chairman and CEO of Insmed Pharmaceuticals, Inc.,
and served as a principal at McManus Associates, a healthcare research and management firm, whose clients included Merck, Bristol
Myers Squibb and American Diabetes Association. Mr. Logan was also Executive Vice President and Chief Operating Officer and board
member at Bausch &amp; Lomb. </FONT>He <FONT STYLE="font-family: Times New Roman, Times, Serif">earned a Bachelor of Arts degree
in Biology from Hiram College. He was a Woodrow Wilson Fellow at New York University and has a PMD from Harvard University.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The search for Ms. Tunstall was conducted by Spencer Stuart,
a worldwide leader in director search and other board advisory services for more than 25 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>About STAAR Surgical</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STAAR, which has been dedicated solely to ophthalmic surgery
for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye and delivery systems therefor. All
of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive
surgery as an alternative to LASIK is called an Implantable Collamer&reg; Lens or &quot;ICL.&quot; A lens used to replace the
natural lens after cataract surgery is called an intraocular lens or &quot;IOL.&quot; Over 400,000 Visian ICLs have been implanted
to date; to learn more about the ICL go to: <FONT STYLE="color: Blue"><U>www.visianinfo.com</U></FONT>. STAAR has approximately
300 full time employees and markets lenses in over 60 countries. Headquartered in Monrovia, CA, it manufactures in the following
locations: Nidau, Switzerland; Aliso Viejo, CA; and Monrovia, CA. For more information, please visit the Company's website at
www.staar.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Safe Harbor</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All statements in this press release that are not statements
of historical fact are forward-looking statements, including statements about any of the following: any projections of financial
items; the potential future performance of the company or prospects for achieving such potential future performance; and statements
regarding expectations for future success. Important additional factors that could cause actual results to differ materially from
those indicated by such forward-looking statements are set forth in the company&rsquo;s Annual Report on Form 10-K for the year
ended December 28, 2012, under the caption &ldquo;Risk Factors,&rdquo; which is on file with the Securities and Exchange Commission
and available in the &ldquo;Investor Information&rdquo; section of the company&rsquo;s website under the heading &ldquo;SEC Filings.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These statements are based on expectations and assumptions as
of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ
materially from those described in the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 34%; padding: 0; text-indent: 0">CONTACT:</td>
    <TD STYLE="width: 33%; padding: 0; text-indent: 0"><b>Investors</b></td>
    <TD STYLE="width: 33%; padding: 0; text-indent: 0"><b>Media</b></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">EVC Group</td>
    <TD STYLE="padding: 0; text-indent: 0">EVC Group</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">Doug Sherk, 415-652-9100</td>
    <TD STYLE="padding: 0; text-indent: 0">Janine McCargo </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">Leigh Salvo, 415-568-9348</td>
    <TD STYLE="padding: 0; text-indent: 0">646-688-0425</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!(`,@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W6X6ZCR]L
MP?UC?^AJI'K2Y82V\HV??\L%RG^\OWA^6/>M6JE[IT%\%+[DF3_5S1G:Z?0_
MTZ4FGT&O,6UU&RO1_HUU%(?[JMR/J.M6JY#4HUM'QKMFMS;D@+?P+M<>F\#_
M`#]:ECTR_,`N-"UYI8CT28[Q],\X^F!4\[[#Y3JJ*XN;7?$^F$_;-.26,?\`
M+14)_53@4R/XAK_RVTTCW67_`.M2]I'J'(SK(;@2:G=6^>8DC/Y[O\*MUPB>
M)#9W;ZU)`S07NZ-8PW39MQS^)IS_`!!=V"P:9DG@$R9_3%'M(]1\C.YHKCH=
M1\6ZG_J+2*T0]'=,8_[ZSG\!3[O3UM(?.\0:W-+GI!&VT-[8[_D*?/V0N4Z&
MXU>PM7\N2Y3S"<"-/G<G_=&35<ZM))+Y-O:OYF,[9/O`>I4=!_O$5FZ9:3WL
M8-G;#2K`\;E'[^4?[W8>_P#.N@M;2"RA$5O&$3J<=2?4GN?>A-L'9!!',!NG
MDRW]U>%'^-3T459(4444`%%%%`!1110`4444`%%%%`!1110`4444`-DC26-H
MY%5T88*L,@BN,U71;[0)WU+0Y'$/66#K@?3N/Y5VM%3**D-.QSNA>+;75ML$
M^+>[Z;2?E;Z'^G\ZU;K2-.O<FXLX78_Q;<-^8YKA_%6A6\6J*]A+%&TG,L98
M*(_?/0`^GY5T?AS5K=T336U'[9=(I.\*0,#L">3]:B,M>61375&@^@:8]G#:
M-:@P0L61-QX)Z\YR:LV]C96*DV]M#"`.2J@?F:LUQ?B?4X-322QM-46"2)BL
MD+C:LA'^UT[=^*J5HJXE=DFM^-$B<VFDJ)YR<>;C*@^P[G]/K4^B>&9&E&I:
MTQGNV^98W.0GU]_;M_*KX+T6UA#7<SI)>J2`G_/,>OOGUKLZF*<O>D-NVB"H
MKFYAL[:2XN)%CAC7<[MT`J6L;Q3I-QK?AZYL;298KABKQLW3<K!@#^5;12;2
M9F]BZ+NX=!(EA+L(R`S*K'\">/QQ4%KKUI=6=]<JDZ+8LRSK)'M92JAB,?0U
MRJ>-/$&D*$\0>&;DA!AKFS^=3[XZ#\ZW-"U[0?%$-V+%@S2C_289%VN01MY'
M<8P,BM'3:5VM/(2E<LVGB&.\TEM333[U+4(9`TBJI90,Y`W9QC\Z9I?B6#6=
M+.HV%G=S0`E<`(&)'7`+5<UA53P_?JH`46L@`'0#8:YCX5_\B5'_`-=Y/Z46
MBX.5NH7=['2Z-K-OKEDUU;1S1JDC1,DZ;65AU!%,U;Q!8Z-=:?;W;E9+Z;RH
M\=O<^V2!^-7X;>&W,IBC5#*YD?'\3$`$_H*X;QCIEOXC\.7=XDT7VR)O.M!O
M&=B9X'^\-Q_%?2E!1E+78&VD=]17/^"]>'B'PS;7;-FX0>5./]M>_P"(P?QK
M5U*Z^R6;,K*LKD1Q[C@;CP,^PZ_0&I<6I<K&G=7*MAX@L=1UG4-+MW)N+$J)
M,XP<]<?0\'WK5/`/&?:O+?$`@\'^,M,U^RE1K2<"WO`C`D]BQQU)'/U6O459
M70.I#*PR".A%54@E9K9BB[Z,Q+CQ3:6NOVVB2V]R+VX3?&H"E2.>^[_9-/O?
M$MEI=W!!J<<UF)SMCFD4&,GT+`G!^N*Y'Q`Q7XR:$P1G(M?NKC)_UGK5OQ_&
M-6M["PO2=-L3<AWO)QN&<$!1MS@\GEB!Q6BIQO%=T+F>IUU[JD5C-#$Z.QEZ
M%<8%%6(88DMX8TPZ1J`C'G@#@YHK#0K4FHHHI#"JT\,UQE//,,??ROO'\>WX
M?G5FB@#/BT/3(HW06<3;P0S.-S-GKDGFO/4MW\.>,HD)/EI*,,>Z-W_(UZE7
M'>/=/$EK;Z@H^:)MCD?W3T_7^=95(Z770N#ULSJKVX%I8SW)Z11L_P"0S7G'
MA+2O[6UIKFX&^&`[WW?Q-V']?PKJO$%\6\%F=3\UQ%'C\<$_IFK'A+3Q8:!!
MD8DG_>M^/3],427-)`M(ER71;!Y!*D/D3+TD@.QA^77\:M0K/'\LD@E'9\8;
M\>W\JFHK2R(N%9.O:A=Z;%9SVMK-=*;D)/'"A=O+*MD@#T.#6M36;:,[6/T%
M4G9Z@RM'J=E)'O%P@'H_RL/J#R*YW2]#5_'-[K\%N;:U:W$*@KL,[D@L^/3@
M#D<GFNI\[_IG)_WS1YW_`$SD_P"^::E:]NHFKE+7)471KV(D^9);R*B@$ECM
M/`KF_AHKV?A6.TN8Y(;CSG/ER(5./QKL?._Z9R?]\T>=_P!,Y/\`OFFIVBXA
M;6Y1U.ZCV?8Q(5>9MCL`?D7&6.?IP/<BKR)$(U*(H3'&!VH\[_IG)_WS1YW_
M`$SD_P"^:F^@SSO0XY/"_C^^MH(97T74!YBR)&Q2)N2`3CC!W#Z$5VL=Q#>Z
MKG=E(5VQ@J?F<C)/X#C\6J_YW_3.3_OFCSO^F<G_`'S5SJ<SOU)4;&1XITFV
MUCP[=6,Q1#*O[IR/NR#E3^8_+-8_@'5[C_A&X[+5H9K>YLSY0,T;+O3^$C([
M=/P'K77^=_TSD_[YH\[_`*9R?]\TE/W>5CMK<\^UE7F^*^BW\<4KVD5OMDG6
M-BBG]YP3CW'YUT/C6PEUOP7?6]DAEF95>-0.6*L"<>^`:Z#SO^F<G_?-'G?]
M,Y/^^:;J:Q:Z"Y=_,P_!UXLOAC3;>3S$N88%BDCD0JRE1CD&BMU9-QQL8?44
M5$G=W&E9#Z***0PHHHH`*I:O:?;M(NK;&2\9V_[PY'Z@5=HH:N!Q$ZG4?"NA
MVBD_OIUC)'8+N6NV50JA5&`!@"N:T^T*ZC96X&([6:Z8#VR-O_H==-4014F%
M%%%62%5KZ:>"VWV\7FON&5'7;GD@=SCM5FHY88YPHD4-M.X>Q]:&!%870N[;
MS`ZO\Q7Y5*D8/0@\@^M,6ZE;5YK3Y?+2!)`<<Y8L/_9?UJS%#'`FR)`JDECC
MN3U/UIDMK!-()'C!<+MW#@X],CM2U&%I(\UI%))MW,N3M&!68^K3KJ4EJ%1B
M+A8D4J1N!56/S9QD`GCOBMA5"J%4``#``[5`UC:N)-T*-YC!WR.I'0_6AI]`
M1++((HGD()"*6('4XK.AU"9K.SNY7B1;EDQ&$8X#=!D=_?&*U!P,576PM4*[
M8$`5MZKV#>H'0&AW`==RM#9S2IC<B,PSTR!FDLY6GLH)GQNDC5SCIDC-2R1I
M+&T;J&1AA@>XHCC2&-8XU"HHPH'84=1%"WNKJ^CN)(#"@CE>)%<$Y*G!W<\<
M]JT:@-G;^8TGE*&<Y;'&X^X[U,RAE*D<$8-"&9]OJ@FU-[9@HC=2T#@\O@X8
M']"/:K&HW#VFFW-S&`7BB9P&'!P,U(;6`K$#&N(<>7_L\8XITL23Q-%*H9&&
M&4]"*-;!H$;%HD+$;BH)Q138[:&)]Z)AL;<Y)X]**8B6BBB@`HHHH`****`*
MD-MLU&:;&`1Q^.,_^@BK=%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
,0`4444`%%%%`'__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
